Keyphrases
Neuroendocrine Neoplasms
100%
64Cu-DOTATATE
66%
DOTATATE PET
66%
Gallium-68
57%
Positron Emission Tomography-computed Tomography (PET-CT)
57%
NODAGA
42%
Positron Emission Tomography
34%
Lesion Detection
23%
Prospective Phase II Study
22%
PET Imaging
22%
Phase II Trial
22%
AE105
22%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
22%
Progression-free Survival
20%
SUVmax
17%
Integrin
15%
Image Quality Detection
15%
After Injection
14%
Artificial Intelligence
14%
Receptor Targets
14%
Angiogenesis
13%
Lesion number
13%
Tumor
12%
Overall Survival
12%
DOTATATE
12%
Prostate Cancer
12%
PET Image
12%
First-in-human
11%
Chronic Myocardial Infarction
11%
Active Sites
11%
Peptide Targeting
11%
Detection Efficiency
11%
Porcine Model
11%
Dose Reduction
11%
C(RGDyK)
11%
Tissue Factor
11%
Primary Cancer
11%
18F-labeled
11%
PET-MRI
11%
Metastatic Cancer
11%
Companion Diagnostics
11%
Receptor-targeted Therapy
11%
Tumor Segmentation
11%
Denoising
11%
Detection Accuracy
11%
Gastrin-releasing Peptide Receptor (GRPr)
11%
United States
11%
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
11%
Total Tumor Volume
11%
Tumor Delineation
11%
Medicine and Dentistry
Neuroendocrine Tumor
100%
Copper 64
77%
Neoplasm
61%
Positron Emission Tomography
58%
Positron Emission Tomography
58%
Positron Emission Tomography-Computed Tomography
51%
Gallium 68
36%
Prognostication
34%
Phase II Trials
22%
Urokinase Receptor
22%
Progression Free Survival
18%
Diagnosis
18%
Image Quality
17%
Malignant Neoplasm
16%
Integrin
15%
Radioactive Tracer
14%
Metastatic Carcinoma
13%
Targeted Therapy
13%
Angiogenesis
12%
Prostate Cancer
12%
Primary Tumor
12%
Overall Survival
11%
Fluorine-18
11%
Factor VII
11%
Drug Dose Reduction
11%
Low Drug Dose
11%
Gastrin Releasing Peptide Receptor
11%
Myocardial Infarction
11%
Thromboplastin
11%
Prostatectomy
11%
Glioblastoma
11%
Somatostatin Receptor
9%
Prostate Specific Antigen
9%
Infarction
6%
False Positive Result
6%
Myocardium
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neuroendocrine Tumor
46%
Neoplasm
40%
Gallium 68
36%
Copper 64
33%
Malignant Neoplasm
16%
Integrin
15%
Prostate Cancer
12%
Metastasis
12%
Tracer
12%
Fluorine 18
11%
Satoreotide Trizoxetan
11%
Primary Tumor
11%
Blood Clotting Factor 7
11%
Porcine Model
11%
Gastrin Releasing Peptide Receptor
11%
Phase II Trials
11%
Thromboplastin
11%
Heart Infarction
11%
Gastroenteropancreatic Neuroendocrine Tumor
11%
Prostate Specific Antigen
11%
Preclinical Study
11%
Urokinase Receptor
11%
Glioblastoma
11%
Infarction
6%
Antigen
5%
Somatostatin Receptor
5%